February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
The use of TDXd for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer – Dana-Farber’s Breast Oncology Center
Oct 15, 2024, 19:00

The use of TDXd for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

Check out our newest treatment guideline on the use of trastuzumab deruxtecan (TDXd) for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer.”

More posts featuring Dana-Farber’s Breast Oncology Center.